A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Kjeldsen, Julie Westerlin, Lorentzen, Cathrine Lund, Martinenaite, Evelina, Ellebaek, Eva, Donia, Marco, Holmstroem, Rikke Boedker, Klausen, Tobias Wirenfeldt, Madsen, Cecilie Oelvang, Ahmed, Shamaila Munir, Weis-Banke, Stine Emilie, Holmström, Morten Orebo, Hendel, Helle Westergren, Ehrnrooth, Eva, Zocca, Mai-Britt, Pedersen, Ayako Wakatsuki, Andersen, Mads Hald, Svane, Inge Marie
Published in Nature medicine (01.12.2021)
Published in Nature medicine (01.12.2021)
Get full text
Journal Article
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Machiels, Jean-Pascal H, Prof, Haddad, Robert I, MD, Fayette, Jérôme, MD, Licitra, Lisa F, MD, Tahara, Makoto, MD, Vermorken, Jan B, Prof, Clement, Paul M, Prof, Gauler, Thomas, MD, Cupissol, Didier, MD, Grau, Juan José, MD, Guigay, Joël, Prof, Caponigro, Francesco, MD, de Castro, Gilberto, PhD, de Souza Viana, Luciano, MD, Keilholz, Ulrich, Prof, del Campo, Joseph M, MD, Cong, Xiuyu Julie, PhD, Ehrnrooth, Eva, MD, Cohen, Ezra E W, MD
Published in The lancet oncology (01.05.2015)
Published in The lancet oncology (01.05.2015)
Get full text
Journal Article
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial
Lorentzen, Cathrine Lund, Martinenaite, Evelina, Kjeldsen, Julie Westerlin, Holmstroem, Rikke Boedker, Mørk, Sofie Kirial, Pedersen, Ayako Wakatsuki, Ehrnrooth, Eva, Andersen, Mads Hald, Svane, Inge Marie
Published in Frontiers in immunology (17.10.2022)
Published in Frontiers in immunology (17.10.2022)
Get full text
Journal Article
Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
Kjeldsen, Julie Westerlin, Lorentzen, Cathrine Lund, Martinenaite, Evelina, Ellebaek, Eva, Donia, Marco, Holmstroem, Rikke Boedker, Klausen, Tobias Wirenfeldt, Madsen, Cecilie Oelvang, Ahmed, Shamaila Munir, Weis-Banke, Stine Emilie, Holmström, Morten Orebo, Hendel, Helle Westergren, Ehrnrooth, Eva, Zocca, Mai-Britt, Pedersen, Ayako Wakatsuki, Andersen, Mads Hald, Svane, Inge Marie
Published in Nature medicine (01.04.2022)
Published in Nature medicine (01.04.2022)
Get full text
Journal Article
Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab
Lorentzen, Cathrine Lund, Kjeldsen, Julie Westerlin, Ehrnrooth, Eva, Andersen, Mads Hald, Marie Svane, Inge
Published in Journal for immunotherapy of cancer (01.05.2023)
Published in Journal for immunotherapy of cancer (01.05.2023)
Get full text
Journal Article
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials
Schuler, Martin, Paz-Ares, Luis, Sequist, Lecia V., Hirsh, Vera, Lee, Ki Hyeong, Wu, Yi-Long, Lu, Shun, Zhou, Caicun, Feng, Jifeng, Ellis, Stuart H., Samuelsen, Carl H., Tang, Wenbo, Märten, Angela, Ehrnrooth, Eva, Park, Keunchil, Yang, James Chih-Hsin
Published in Lung cancer (Amsterdam, Netherlands) (01.07.2019)
Published in Lung cancer (Amsterdam, Netherlands) (01.07.2019)
Get full text
Journal Article
Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study
Jørgensen, Nicolai Grønne, Kaae, Jeanette, Grauslund, Jacob Handlos, Met, Özcan, Nielsen, Signe Ledou, Pedersen, Ayako Wakatsuki, Svane, Inge Marie, Ehrnrooth, Eva, Andersen, Mads Hald, Zachariae, Claus, Skov, Lone
Published in Cancers (22.02.2021)
Published in Cancers (22.02.2021)
Get full text
Journal Article
Phase 2 study of the IDO/PD-L1-targeted immune-modulatory vaccine, IO102-IO103, plus pembrolizumab as first-line treatment for metastatic non–small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), or urothelial bladder cancer (UBC)
Riess, Jonathan W., Shaw, Paul, Srinivasan, Devraj, Garrido, Pilar, Vuky, Jacqueline, Chaney, Marya F., O'Neill, Shane, Alavi, Alireza, McDowell, Diane Opatt, Ehrnrooth, Eva, Cohen, Ezra
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma
Svane, Inge Marie, Nair, Santosh M., Puzanov, Igor, Robert, Caroline, Hassel, Jessica Cecile, Sandhu, Shahneen, Vedel Christiansen, Anita, Lowery, Kath, Pemberton, Kristine, Al Hajj, Mohammad, Diede, Scott J., Ehrnrooth, Eva, Eggermont, Alexander M.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Efficacy and safety of IO103 a novel anti PD-L1 vaccine in basal cell carcinoma
Jørgensen, Nicolai Grønne, Kaae, Jeanette, Grauslund, Jacob Handlos, Met, Özcan, Svane, Inge Marie, Ehrnrooth, Eva, Andersen, Mads Hald, Zachariae, Claus, Skov, Lone
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study
Gadgeel, Shirish, Goss, Glenwood, Soria, Jean-Charles, Felip, Enriqueta, Georgoulias, Vassilis, Lu, Shun, Cobo, Manuel, Syrigos, Konstantinos, Lee, Ki Hyeong, Göker, Erdem, Guclu, Salih Z, Isla, Dolores, Morabito, Alessandro, Dupuis, Nicholas, Bühnemann, Claudia, Krämer, Nicole, Solca, Flavio, Ehrnrooth, Eva, Ardizzoni, Andrea
Published in Lung cancer (Amsterdam, Netherlands) (01.07.2017)
Published in Lung cancer (Amsterdam, Netherlands) (01.07.2017)
Get full text
Journal Article
Abstract CT535: High clinical efficacy in poor prognosis patients with metastatic melanoma treated with an IDO/PD-L1 peptide vaccine in combination with nivolumab
Kjeldsen, Julie W., Lorentzen, Cathrine L., Martinenaite, Evelina, Ellebaek, Eva, Donia, Marco, Ehrnrooth, Eva, Andersen, Mads H., Svane, Inge Marie
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article
Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial
Goss, Glenwood D, Felip, Enriqueta, Cobo, Manuel, Lu, Shun, Syrigos, Konstantinos, Lee, Ki Hyeong, Göker, Erdem, Georgoulias, Vassilis, Li, Wei, Guclu, Salih, Isla, Dolores, Min, Young Joo, Morabito, Alessandro, Ardizzoni, Andrea, Gadgeel, Shirish M, Fülöp, Andrea, Bühnemann, Claudia, Gibson, Neil, Krämer, Nicole, Solca, Flavio, Cseh, Agnieszka, Ehrnrooth, Eva, Soria, Jean-Charles
Published in JAMA oncology (01.09.2018)
Published in JAMA oncology (01.09.2018)
Get more information
Journal Article
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
Felip, Enriqueta, Hirsh, Vera, Popat, Sanjay, Cobo, Manuel, Fülöp, Andrea, Dayen, Charles, Trigo, José M., Gregg, Richard, Waller, Cornelius F., Soria, Jean-Charles, Goss, Glenwood D., Gordon, James, Wang, Bushi, Palmer, Michael, Ehrnrooth, Eva, Gadgeel, Shirish M.
Published in Clinical lung cancer (01.01.2018)
Published in Clinical lung cancer (01.01.2018)
Get full text
Journal Article
LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts)
Burtness, Barbara, Haddad, Robert I., Dinis, José, Trigo Perez, Jose Manuel, Yokota, Tomoya, Viana, Luciano De Souza, Romanov, Ilya, Vermorken, Jan Baptist, Bourhis, Jean, Tahara, Makoto, Segalla, J.G.M., Psyrri, Amanda, Vasilevskaya, Irina, Nangia, Chaitali Singh, Chaves-Conde, Manuel, Wang, Bushi, Gibson, Neil, Ehrnrooth, Eva, Harrington, Kevin, Cohen, Ezra E.W.
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover
Cupissol, Didier, Seiwert, Tanguy Y., Fayette, Jérôme, Ehrnrooth, Eva, Blackman, Alice Sarah, Cong, Xiuyu Julie, Cohen, Ezra E.W.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Abstract 3701: Phase II study of BIBF1120 in recurrent glioblastoma multiforme
Lassen, Ulrik, Mau-Soerensen, Morten, Muhic, Aida, Ehrnrooth, Eva, Poulsen, Hans S.
Published in Cancer research (Chicago, Ill.) (15.04.2012)
Published in Cancer research (Chicago, Ill.) (15.04.2012)
Get full text
Journal Article
Evaluation of VeriStrat, a serum proteomic test, in the randomized, open-label, phase 3 LUX-Lung 8 (LL8) trial of afatinib (A) versus erlotinib (E) for the second-line treatment of advanced squamous cell carcinoma (SCC) of the lung
Goss, Glenwood D., Lee, Ki Hyeong, Felip, Enriqueta, Cobo, Manuel, Syrigos, Konstantinos N., Göker, Erdem, Georgoulias, Vassilis, Guclu, Salih Z., Isla, Dolores, Min, Young J., Morabito, Alessandro, Close, Sandra, Dupuis, Nicholas, Chand, Vikram K., Solca, Flavio, Krämer, Nicole, Gibson, Neil, Ehrnrooth, Eva, Soria, Jean-Charles
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article